This observational study will assess factors leading to dose reductions/treatment discontinuations and the effect on sustained virological response in patients with chronic hepatitis C receiving a long-acting interferon (e.g. Pegasys/peginterferon alfa-2a) and ribavirin. Data will be collected from each patient for the duration of their treatment and for up to 6 months thereafter.
Study Type
OBSERVATIONAL
Enrollment
4,459
Correlation between baseline patient characteristics and safety related dose reductions/treatment discontinuations of the long-acting interferon or ribavirin
Time frame: 4 years
Correlation between safety related dose reductions/treatment discontinuations and sustained virological response (SVR: defined as HCV RNA <50 IU/mL at 24 weeks after completion of treatment)
Time frame: 4 years
Correlation of on-treatment factors and dose reduction/treatment discontinuation
Time frame: 4 years
Correlation between degree of dose reductions/treatment interruptions (percentage of actual exposure/treatment administrations in relation to target exposure) and SVR
Time frame: 4 years
Comparison of on-treatment virological response (rapid virological response, early virological response) in treatment-naïve and treatment experienced patients
Time frame: 4 years
Safety: Incidence of adverse events
Time frame: 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Elbasan, Albania
Unnamed facility
Tirana, Albania
Unnamed facility
Algiers, Algeria
Unnamed facility
Bahrain, Bahrain
Unnamed facility
Manama, Bahrain
Unnamed facility
Antwerp, Belgium
Unnamed facility
Antwerp, Belgium
Unnamed facility
Bruges, Belgium
Unnamed facility
Brussels, Belgium
Unnamed facility
Brussels, Belgium
...and 250 more locations